Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2150755 | 0.86 | ROCK2 (0.69) | ROCK2MEN1KMT2AGAACYP11B1 | |
| SCHEMBL2151325 | 0.84 | ROCK2 (0.72) | ROCK2MEN1KMT2AGAACYP11B1 | |
| SCHEMBL27520697 | 0.78 | ROCK2 (0.55) | ROCK2MEN1KMT2AGAACYP11B1 | |
| SCHEMBL16265336 | 0.78 | ROCK2 (0.55) | ROCK2MEN1KMT2AGAACYP11B1 | |
| SCHEMBL14880372 | 0.78 | ROCK2 (0.55) | ROCK2MEN1KMT2AGAACYP11B1 | |
| SCHEMBL31286060 | 0.77 | ROCK2 (0.51) | ROCK2MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL22276897 | 0.77 | ROCK2 (0.51) | ROCK2MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL16265145 | 0.77 | ROCK2 (0.51) | ROCK2MEN1KMT2AGAACYP11B1 | |
| SCHEMBL17704392 | 0.75 | ROCK2 (0.56) | ROCK2MEN1KMT2AGAACYP11B1 | |
| SCHEMBL16159258 | 0.75 | ROCK2 (0.56) | ROCK2MEN1KMT2AGAACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114245796-B | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| EP-3990454-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114245796-A | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease | 比奥根MA公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2020263980-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| EP-2523952-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB Science (FR) | 2012-11-21 | — | — | EP | disclosed |
| US-20110201648-A1 | POLY-HETEROARYL DERIVATIVES FOR THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201648-A1 | POLY-HETEROARYL DERIVATIVES FOR THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086085-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010049915-A1 | POLY-HETEROARYL DERIVATIVES FOR THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SYK, LTK, MERTK | ROCK2 889/4885MEN1 3607/4885KMT2A 1415/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | ROCK2 1669/4885MEN1 601/4885KMT2A 291/4885 |
| US-20110201648-A1 | POLY-HETEROARYL DERIVATIVES FOR THE TREATMENT OF CANCER | ALOX15B, ALOX5, ALOX12 | ROCK2 2656/4885MEN1 2491/4885KMT2A 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.